Journal
CLINICAL LYMPHOMA & MYELOMA
Volume 6, Issue 4, Pages 329-332Publisher
CIG MEDIA GROUP, LP
DOI: 10.3816/CLM.2006.n.008
Keywords
efalizumab; infliximab; mycosis fungoides; Sezary syndrome
Categories
Funding
- NCI NIH HHS [CA16672, K24-CA86815] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [P30CA016672, K24CA086815] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Systemic immunomodulatory agents have recently been approved for the treatment of rheumatoid arthritis and psoriasis. Although lymphomas are known to emerge in the setting of immunosuppressive therapy, it has not been well described or established for the newer biologic immune response modifiers. Herein, we describe 2 patients who developed unusual CD8(+) cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab. The mechanisms and occurrence of lymphoma after immune response modifiers are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available